Recommendations and considerations for the use of biologics in orthopedic surgery

BioDrugs

Volumn 26, Issue 4, 2012, Pages 245-256

  Zwingenberger, Stefan ^a,b   Nich, Christophe ^a,c,d   Valladares, Roberto D ^a   Yao, Zhenyu ^a   Stiehler, Maik ^b   Goodman, Stuart B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Paris university   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biological products; Bone morphogenetic proteins; Orthopaedic surgery

Indexed keywords

BIOMATERIAL; CALCIUM OXIDE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE CERAMIC; CALCIUM SILICATE; CALCIUM SULFATE; COLLAGEN TYPE 1; FIBRIN; FIBROBLAST GROWTH FACTOR; HYDROXYAPATITE; NANOCOMPOSITE; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE; PHOSPHORUS PENTOXIDE; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SILICATE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

BIOCOMPATIBILITY; BONE ALLOGRAFT; BONE CONDUCTION; BONE DEFECT; BONE DEVELOPMENT; BONE GRAFT; BONE GROWTH; BONE MARROW BIOPSY; BONE MATRIX; BONE REGENERATION; BONE REMODELING; CELL COUNT; CELL DEDIFFERENTIATION; CELL EXPANSION; CELL THERAPY; CHEMICAL COMPOSITION; DNA MODIFICATION; ENCHONDRAL OSSIFICATION; EX VIVO GENE TRANSFER; FIBULA GRAFT; GENE THERAPY; GENE TRANSFER; HORMONAL THERAPY; HUMAN; INTERNAL FIXATOR; INTRAMEDULLARY NAIL; MEDICAL RESEARCH; MESENCHYMAL STROMA CELL; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOPOROSIS; OSTEOTOMY; POROSITY; PRIORITY JOURNAL; REVIEW; SPINE FUSION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING;

BIOLOGICAL AGENTS; BIOMIMETIC MATERIALS; BONE CEMENTS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE SUBSTITUTES; BONE TRANSPLANTATION; CERAMICS; CHONDROCYTES; GENETIC THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ORTHOPEDIC PROCEDURES; PRACTICE GUIDELINES AS TOPIC;

EID: 84863425886     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11631680-000000000-00000     Document Type: Review

References (168)

1. Khan SN, Cammisa Jr FP, Sandhu HS, et al. The biology of bone grafting. J Am Acad Orthop Surg 2005 Feb; 13 (1): 77-86
2. Kappe T, Cakir B, Mattes T, et al. Infections after bone allograft surgery: A prospective study by a hospital bone bank using frozen femoral heads from living donors. Cell Tissue Bank 2010 Aug; 11 (3): 253-9
3. Goldberg VM, Akhavan S. Biology of bone grafts. In: Lieberman JR, Friedlaender GE, editors. Bone regeneration and repair: Biology and clinical applications. Totowa (NJ): Humana Press, 2005: 57-65
4. Ullmark G, Obrant KJ. Histology of impacted bone-graft incorporation. J Arthroplasty 2002 Feb; 17 (2): 150-7
5. van der Donk S, Buma P, Slooff TJ, et al. Incorporation of morselized bone grafts: A study of 24 acetabular biopsy specimens. Clin Orthop Relat Res 2002 Mar; (396): 131-141
6. Hamer AJ, Suvarna SK, Stockley I. Histologic evidence of cortical allograft bone incorporation in revision hip surgery. J Arthroplasty 1997 Oct; 12 (7): 785-9
7. Hooten Jr JP, Engh CA, Heekin RD, et al. Structural bulk allografts in acetabular reconstruction: Analysis of two grafts retrieved at post-mortem. J Bone Joint Surg Br 1996 Mar; 78 (2): 270-5
8. Enneking WF, Mindell ER. Observations on massive retrieved human allografts. J Bone Joint Surg Am 1991 Sep; 73 (8): 1123-1142
9. Schreurs BW, Slooff TJ, Buma P, et al. Acetabular reconstruction with impacted morsellised cancellous bone graft and cement: A 10- to 15-year followup of 60 revision arthroplasties. J Bone Joint Surg Br 1998 May; 80 (3): 391-5
10. Azuma T, Yasuda H, Okagaki K, et al. Compressed allograft chips for acetabular reconstruction in revision hip arthroplasty. J Bone Joint Surg Br 1994 Sep; 76 (5): 740-4
11. Berry DJ, Müller ME. Revision arthroplasty using an anti-protrusio cage for massive acetabular bone deficiency. J Bone Joint Surg Br 1992 Sep; 74 (5): 711-5
12. Gill TJ, Sledge JB, Müller ME. The Bürch-Schneider anti-protrusio cage in revision total hip arthroplasty: Indications, principles and long-term results. J Bone Joint Surg Br 1998 Nov; 80 (6): 946-953
13. Gie GA, Linder L, Ling RS, et al. Impacted cancellous allografts and cement for revision total hip arthroplasty. J Bone Joint Surg Br 1993 Jan; 75 (1): 14-21
14. Rogers BA, Sternheim A, Backstein D, et al. Proximal femoral allograft for major segmental femoral bone loss: A systematic literature review. Adv Orthop 2011; 2011: 257572
15. Martin WR, Sutherland CJ. Complications of proximal femoral allografts in revision total hip arthroplasty. Clin Orthop Relat Res 1993 Oct; (295): 161-7
16. Clatworthy MG, Ballance J, Brick GW, et al. The use of structural allograft for uncontained defects in revision total knee arthroplasty: A minimum five-year review. J Bone Joint Surg Am 2001 Mar; 83-A (3): 404-411
17. Engh GA, Ammeen DJ. Use of structural allograft in revision total knee arthroplasty in knees with severe tibial bone loss. J Bone Joint SurgAm2007 Dec; 89 (12): 2640-7
18. Backstein D, Safir O, Gross A. Management of bone loss: Structural grafts in revision total knee arthroplasty. Clin Orthop RelatRes 2006May; 446: 104-112
19. Mnaymneh W, Emerson RH, Borja F, et al. Massive allografts in salvage revisions of failed total knee arthroplasties. Clin Orthop Relat Res 1990 Nov; (260): 144-153
20. An HS, Lynch K, Toth J. Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: Differences among freeze-dried, frozen, and mixed grafts. J Spinal Disord 1995 Apr; 8 (2): 131-135
21. Gibson S, McLeod I, Wardlaw D, et al. Allograft versus autograft in instrumented posterolateral lumbar spinal fusion: A randomized control trial. Spine 2002 Aug; 27 (15): 1599-1603
22. Gitelis S, Piasecki P, Turner T, et al. Use of a calcium sulfate-based bone graft substitute for benign bone lesions. Orthopedics 2001 Feb; 24 (2): 162-6
23. Kelly CM, Wilkins RM, Gitelis S, et al. The use of a surgical grade calcium sulfate as a bone graft substitute: Results of a multicenter trial. Clin Orthop Relat Res 2001 Jan; (382): 42-50
24. Niu C-C, Tsai T-T, Fu T-S, et al. A comparison of posterolateral lumbar fusion comparing autograft, autogenous laminectomy bone with bone marrow aspirate, and calcium sulphate with bone marrow aspirate: A prospective randomized study. Spine 2009 Dec; 34 (25): 2715-9
25. Ray RD, Ward Jr AA. A preliminary report on studies of basic calcium phosphate in bone replacement. Surg Forum 1951; 429-434
26. Guillemin G, Patat JL, Fournie J, et al. The use of coral as a bone graft substitute. J Biomed Mater Res 1987 May; 21 (5): 557-567
27. Eggli PS, Müller W, Schenk RK. Porous hydroxyapatite and tricalcium phosphate cylinders with two different pore size ranges implanted in the cancellous bone of rabbits: A comparative histomorphometric and histologic study of bony ingrowth and implant substitution. Clin Orthop Relat Res 1988 Jul; (232): 127-138
28. Holmes RE, Bucholz RW, Mooney V. Porous hydroxyapatite as a bone graft substitute in diaphyseal defects: A histometric study. J Orthop Res 1987; 5 (1): 114-121
29. Le Huec JC, Clément D, Brouillaud B, et al. Evolution of the local calcium content around irradiated beta-tricalcium phosphate ceramic implants: In vivo study in the rabbit. Biomaterials 1998 May; 19 (7-9): 733-738
30. Le Huec JC, Schaeverbeke T, Clement D, et al. Influence of porosity on the mechanical resistance of hydroxyapatite ceramics under compressive stress. Biomaterials 1995 Jan; 16 (2): 113-118
31. Bohner M, Baumgart F. Theoretical model to determine the effects of geometrical factors on the resorption of calcium phosphate bone substitutes. Biomaterials 2004 Aug; 25 (17): 3569-3582
32. Oonishi H, Iwaki Y, Kin N, et al. Hydroxyapatite in revision of total hip replacements with massive acetabular defects: 4- to 10-year clinical results. J Bone Joint Surg Br 1997 Jan; 79 (1): 87-92
33. Oonishi H, Kadoya Y, Iwaki H, et al. Hydroxyapatite granules interposed at bone-cement interface in total hip replacements: Histological study of retrieved specimens. J Biomed Mater Res 2000; 53 (2): 174-180
34. Schwartz C, Bordei R. Biphasic phospho-calcium ceramics used as bone substitutes are efficient in the management of severe acetabular bone loss in revision total hip arthroplasties. Eur J Orthop Surg Traumatol 2005 Jun; 15 (3): 191-6
35. KärrholmJ, Hultmark P, Carlsson L, et al. Subsidence of a non-polished stem in revisions of the hip using impaction allograft. Evaluation with radiostereometry and dual-energy X-ray absorptiometry. J Bone Joint Surg Br 1999 Jan; 81 (1): 135-142
36. Eldridge JD, Smith EJ, Hubble MJ, et al. Massive early subsidence following femoral impaction grafting. J Arthroplasty 1997 Aug; 12 (5): 535-540
37. Nich C, Sedel L. Bone substitution in revision hip replacement. Int Orthop 2006 Dec; 30 (6): 525-531
38. Passuti N, Daculsi G, Rogez JM, et al. Macroporous calcium phosphate ceramic performance in human spine fusion. Clin Orthop Relat Res 1989 Nov; (248): 169-176
39. Gaasbeek RDA, Toonen HG, van Heerwaarden RJ, et al. Mechanism of bone incorporation of beta-TCP bone substitute in open wedge tibial osteotomy in patients. Biomaterials 2005 Nov; 26 (33): 6713-9
40. Hernigou P, Roussignol X, Flouzat-Lachaniette CH, et al. Opening wedge tibial osteotomy for large varus deformity with Ceraver resorbable beta tricalcium phosphate wedges. Int Orthop 2010 Feb; 34 (2): 191-9
41. Schwartz C, Liss P, Jacquemaire B, et al. Biphasic synthetic bone substitute use in orthopaedic and trauma surgery: Clinical, radiological and histological results. J Mater Sci Mater Med 1999 Dec; 10 (12): 821-5
42. Jiang S-D, Jiang L-S, Dai L-Y. Surgical treatment of calcaneal fractures with use of beta-tricalcium phosphate ceramic grafting. Foot Ankle Int 2008 Oct; 29 (10): 1015-9
43. Scheer JH, Adolfsson LE. Tricalcium phosphate bone substitute in corrective osteotomy of the distal radius. Injury 2009 Mar; 40 (3): 262-7
44. Uchida A, Araki N, Shinto Y, et al. The use of calcium hydroxyapatite ceramic in bone tumour surgery. J Bone Joint Surg Br 1990 Mar; 72 (2): 298-302
45. Yamamoto T, Onga T, Marui T, et al. Use of hydroxyapatite to fill cavities after excision of benign bone tumours: Clinical results. J Bone Joint Surg Br 2000 Nov; 82 (8): 1117-1120
46. Galois L, Mainard D, Delagoutte JP. Beta-tricalcium phosphate ceramic as a bone substitute in orthopaedic surgery. Int Orthop 2002; 26 (2): 109-115
47. Schindler OS, Cannon SR, Briggs TWR, et al. Composite ceramic bone graft substitute in the treatment of locally aggressive benign bone tumours. J Orthop Surg 2008 Apr; 16 (1): 66-74
48. Zhang Y, Zhang M. Synthesis and characterization of macroporous chitosan/calcium phosphate composite scaffolds for tissue engineering. J Biomed Mater Res 2001 Jun 5; 55 (3): 304-312
49. Ding S-J. Preparation and properties of chitosan/calcium phosphate composites for bone repair. Dent Mater J 2006 Dec; 25 (4): 706-712
50. ItoM,HidakaY,NakajimaM, et al. Effect of hydroxyapatite content on physical properties and connective tissue reactions to a chitosan-hydroxyapatite composite membrane. J Biomed Mater Res 1999 Jun; 45 (3): 204-8
51. Brown W, Chow LC. A new calcium phosphate, water-setting cement. In: Brown PW, editor. Cements Research Progress 1986. Westerville, Ohio: American Ceramic Society, 1987: 352-379
52. Frayssinet P, Rouquet N, Mathon D, et al. Histological integration of allogeneic cancellous bone tissue treated by supercritical CO2 implanted in sheep bones. Biomaterials 1998 Dec; 19 (24): 2247-2253
53. Xu HHK, Quinn JB, Takagi S, et al. Synergistic reinforcement of in situ hardening calcium phosphate composite scaffold for bone tissue engineering. Biomaterials 2004 Mar; 25 (6): 1029-1037
54. Xu HHK, Quinn JB, Takagi S, et al. Processing and properties of strong and non-rigid calcium phosphate cement. J Dent Res 2002 Mar; 81 (3): 219-224
55. Sanchez-Sotelo J, Munuera L, Madero R. Treatment of fractures of the distal radius with a remodellable bone cement: A prospective, randomised study using Norian SRS. J Bone Joint Surg Br 2000 Aug; 82 (6): 856-863
56. Lobenhoffer P, Gerich T, Witte F, et al. Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures: A prospective study of twenty-six cases with twenty-month mean follow-up. J Orthop Trauma 2002 Mar; 16 (3): 143-9
57. Thordarson DB, Hedman TP, Yetkinler DN, et al. Superior compressive strength of a calcaneal fracture construct augmented with remodelable cancellous bone cement. J Bone Joint Surg Am 1999 Feb; 81 (2): 239-246
58. Schildhauer TA, Bauer TW, Josten C, et al. Open reduction and augmentation of internal fixation with an injectable skeletal cement for the treatment of complex calcaneal fractures. J Orthop Trauma 2000 Jul; 14 (5): 309-317
59. Welkerling H, Raith J, Kastner N, et al. Painful soft-tissue reaction to injectable Norian SRS calcium phosphate cement after curettage of enchondromas. J Bone Joint Surg Br 2003 Mar; 85 (2): 238-9
60. Maus U, Andereya S, Gravius S, et al. BMP-2 incorporated in a tricalcium phosphate bone substitute enhances bone remodeling in sheep. J Biomater Appl 2008 May; 22 (6): 559-576
61. Hench LL, Paschall HA. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J Biomed Mater Res 1973; 7 (3): 25-42
62. Xynos ID, Edgar AJ, Buttery LD, et al. Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. J Biomed Mater Res 2001 May; 55 (2): 151-7
63. Kaufmann EA, Ducheyne P, Shapiro IM. Effect of varying physical properties of porous, surface modified bioactive glass 45S5 on osteoblast proliferation and maturation. J Biomed Mater Res 2000 Dec; 52 (4): 783-796
64. Bosetti M, VernèE, Brovarone CV, et al. Fluoroapatite glass-ceramic coating on alumina: Surface behavior with biological fluids. J Biomed Mater Res A 2003 Sep; 66 (3): 615-621
65. Hattar S, Berdal A, Asselin A, et al. Behaviour of moderately differentiated osteoblast-like cells cultured in contact with bioactive glasses. Eur Cell Mater 2002 Dec; 4: 61-9
66. Nakamura T, Yamamuro T, Higashi S, et al. A new glass-ceramic for bone replacement: Evaluation of its bonding to bone tissue. J Biomed Mater Res 1985 Aug; 19 (6): 685-698
67. Kitsugi T, Yamamuro T, Nakamura T, et al. Bone bonding behavior of three kinds of apatite containing glass ceramics. J Biomed Mater Res 1986 Dec; 20 (9): 1295-1307
68. Ono K, Yamamuro T, Nakamura T, et al. Quantitative study on osteoconduction of apatite-wollastonite containing glass ceramic granules, hydroxyapatite granules, and alumina granules. Biomaterials 1990 May; 11 (4): 265-271
69. Kasai Y, Takegami K, Uchida A. Mixture ratios of local bone to artificial bone in lumbar posterolateral fusion. J Spinal Disord Tech 2003 Feb; 16 (1): 31-7
70. Schepers E, De Clercq M, Ducheyne P, et al. Bioactive glass particulate material as a filler for bone lesions. J Oral Rehabil 1991 Sep; 18 (5): 439-452
71. Oréfice R, West J, Latorre G, et al. Effect of long-term in vitro testing on the properties of bioactive glass-polysulfone composites. Biomacromolecules 2010 Mar; 11 (3): 657-665
72. Ramay HRR, Zhang M. Biphasic calcium phosphate nanocomposite porous scaffolds for load-bearing bone tissue engineering. Biomaterials 2004 Sep; 25 (21): 5171-5180
73. Webster TJ, Ergun C, Doremus RH, et al. Specific proteins mediate enhanced osteoblast adhesion on nanophase ceramics. J Biomed Mater Res 2000 Sep; 51 (3): 475-483
74. Dalby MJ, Riehle MO, Johnstone H, et al. In vitro reaction of endothelial cells to polymer demixed nanotopography. Biomaterials 2002 Jul; 23 (14): 2945-2954
75. Schneider OD, Loher S, Brunner TJ, et al. Cotton wool-like nanocomposite biomaterials prepared by electrospinning: In vitro bioactivity and osteogenic differentiation of human mesenchymal stem cells. J Biomed Mater Res Part B Appl Biomater 2008 Feb; 84 (2): 350-362
76. Bernhardt A, Lode A, Boxberger S, et al. Mineralised collagen: An artificial, extracellular bone matrix-improves osteogenic differentiation of bone marrow stromal cells. J Mater Sci Mater Med 2008 Jan; 19 (1): 269-275
77. Jie W, Hua H, Lan W, et al. Preliminary investigation of bioactivity of nano biocomposite. J Mater Sci Mater Med 2007 Mar; 18 (3): 529-533
78. Itoh S, Kikuchi M, Koyama Y, et al. Development of a hydroxyapatite/ collagen nanocomposite as a medical device. Cell Transplant 2004; 13 (4): 451-461
79. Dimitriou R, Jones E, McGonagle D, et al. Bone regeneration: Current concepts and future directions. BMC Med 2011; 9: 66
80. Bishop GB, Einhorn TA. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007 Dec; 31 (6): 721-7
81. Betz OB, Betz VM, Abdulazim A, et al. The repair of critical size bone defects using expedited, autologous BMP-2 gene activated fat implants. Tissue Eng Part A 2010 Mar; 16 (3): 1093-1101
82. Jones AL, Bucholz RW, Bosse MJ, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects: A randomized, controlled trial. J Bone Joint Surg Am 2006 Jul; 88 (7): 1431-1441
83. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002 Dec; 84-A (12): 2123-2134
84. Aro HT, Govender S, Patel AD, et al. Recombinant human bone morphogenetic protein-2: A randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am 2011 May; 93 (9): 801-8
85. Calori GM, D'Avino M, Tagliabue L, et al. An ongoing research for evaluation of treatment with BMPs or AGFs in long bone non-union: Protocol description and preliminary results. Injury 2006 Sep; 37 Suppl. 3: 43-50
86. Ekrol I, Hajducka C, Court-Brown C, et al. A comparison of RhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of the distal radius. Injury 2008 Sep; 39 Suppl. 2: 73-82
87. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001; 83-A Suppl. 1 (Pt 2): 151-8
88. Geesink RG, Hoefnagels NH, Bulstra SK, et al. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999 Jul; 81 (4): 710-8
89. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: A prospective analysis of interbody fusion rates and clinical outcomes. Spine J 2007 Jun; 7 (3): 301-7
90. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine 2005 Dec; 3 (6): 436-443
91. GarrisonKR, Shemilt I, Donell S, et al. Bonemorphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; (6): CD006950
92. Helgeson MD, Lehman Jr RA, Patzkowski JC, et al. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. Spine J 2011 Jun; 11 (6): 507-510
93. Baas J, Elmengaard B, Jensen TB, et al. The effect of pretreating morselized allograft bone with rhBMP-2 and/or pamidronate on the fixation of porous Ti and HA-coated implants. Biomaterials 2008 Jul; 29 (19): 2915-2922
94. Al-Zube L, Breitbart EA, O'Connor JP, et al. Recombinant human plateletderived growth factor BB (rhPDGF-BB) and beta-tricalcium phosphate/collagen matrix enhance fracture healing in a diabetic rat model. J Orthop Res 2009 Aug; 27 (8): 1074-1081
95. Lee J-Y, Kim K-H, Shin S-Y, et al. Enhanced bone formation by transforming growth factor-beta1-releasing collagen/chitosan microgranules. J Biomed Mater Res A 2006 Mar; 76 (3): 530-9
96. Granero-MoltóF,Myers TJ,Weis JA, et al.Mesenchymal stemcells expressing insulin-like growth factor-I (MSCIGF) promote fracture healing and restore new bone formation in Irs1 knockout mice: Analyses of MSCIGF autocrine and paracrine regenerative effects. Stem Cells 2011 Oct; 29 (10): 1537-1548
97. Beamer B, Hettrich C, Lane J. Vascular endothelial growth factor: An essential component of angiogenesis and fracture healing. HSS J. Epub 2009 Sep 9
98. Willems WF, Larsen M, Giusti G, et al. Revascularization and bone remodeling of frozen allografts stimulated by intramedullary sustained delivery of FGF-2 and VEGF. J Orthop Res 2011 Sep; 29 (9): 1431-6
99. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 2011 Feb; 39 (2): 266-271
100. Vater C, Kasten P, Stiehler M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater 2011 Feb; 7 (2): 463-477
101. Berghoff WJ, PietrzakWS, RhodesRD. Platelet-rich plasma application during closure following total knee arthroplasty. Orthopedics 2006 Jul; 29 (7): 590-8
102. Hartmann EK, Heintel T, Morrison RH, et al. Influence of platelet-rich plasma on the anterior fusion in spinal injuries: A qualitative and quantitative analysis using computer tomography. Arch Orthop Trauma Surg 2010 Jul; 130 (7): 909-914
103. Sanchez M, Anitua E, Cugat R, et al. Nonunions treated with autologous preparation rich in growth factors. J Orthop Trauma 2009 Jan; 23 (1): 52-9
104. Nin JRV, Gasque GM, Azcárate AV, et al. Has platelet-rich plasma any role in anterior cruciate ligament allograft healing? Arthroscopy 2009 Nov; 25 (11): 1206-1213
105. Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-Articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011 Apr; 19 (4): 528-535
106. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006 Nov; 34 (11): 1774-8
107. Gosens T, Peerbooms JC, van Laar W, et al. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: A double-blind randomized controlled trial with 2-year follow-up.AmJ Sports Med 2011 Jun; 39 (6): 1200-8
108. Gaweda K, Tarczynska M, Krzyzanowski W. Treatment of Achilles tendinopathy with platelet-rich plasma. Int J Sports Med 2010 Aug; 31 (8): 577-583
109. De Jonge S, De Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: A double-blind randomized placebo-controlled trial. Am J Sports Med 2011 Aug; 39 (8): 1623-9
110. Mazzocca AD, McCarthy MBR, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am 2012 Feb; 94 (4): 308-16
111. Han B, Woodell-May J, Ponticiello M, et al. The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. J Bone Joint Surg Am 2009 Jun; 91 (6): 1459-1470
112. Yuan T, Guo S-C, Han P, et al. Applications of leukocyte- and platelet-rich plasma (L-PRP) in trauma surgery. Curr Pharm Biotechnol. Epub 2011 Jul 8
113. Saito N, Murakami N, Takahashi J, et al. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv Drug Deliv Rev 2005 May; 57 (7): 1037-1048
114. Kanematsu A, Yamamoto S, Ozeki M, et al. Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 2004 Aug; 25 (18): 4513-4520
115. Nagahama K, Ueda Y, Ouchi T, et al. Biodegradable shape-memory polymers exhibiting sharp thermal transitions and controlled drug release. Biomacromolecules 2009 Jul; 10 (7): 1789-1794
116. Go DP, Gras SL, Mitra D, et al. Multilayered microspheres for the controlled release of growth factors in tissue engineering. Biomacromolecules 2011 May; 12 (5): 1494-503
117. Wildemann B, Sander A, Schwabe P, et al. Short term in vivo biocompatibility testing of biodegradable poly(D,L-lactide): Growth factor coating for orthopaedic implants. Biomaterials 2005 Jun; 26 (18): 4035-4040
118. Haynesworth SE, Goshima J, Goldberg VM, et al. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13 (1): 81-8
119. Bruder SP, Kurth AA, Shea M, et al. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998 Mar; 16 (2): 155-162
120. Arinzeh TL, Peter SJ, Archambault MP, et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 2003 Oct; 85-A (10): 1927-1935
121. Nishikawa M, MyouiA, Ohgushi H, et al. Bone tissue engineering using novel interconnected porous hydroxyapatite ceramics combined with marrow mesenchymal cells: quantitative and three-dimensional image analysis. Cell Transplant 2004; 13 (4): 367-376
122. Kalia P, Blunn GW, Miller J, et al. Do autologous mesenchymal stem cells augment bone growth and contact to massive bone tumor implants? Tissue Eng 2006 Jun; 12 (6): 1617-1626
123. Korda M, Blunn G, Goodship A, et al. Use of mesenchymal stem cells to enhance bone formation around revision hip replacements. J Orthop Res 2008 Jun; 26 (6): 880-5
124. Bernstein P, Bornhauser M, Gunther KP, et al. Bone tissue engineering in clinical application: Assessment of the current situation. Orthopade 2009 Nov; 38 (11): 1029-1037
125. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007 Apr; 211 (1): 27-35
126. JägerM, JelinekEM,WessKM, et al. Bone marrow concentrate: A novel strategy for bone defect treatment. Curr Stem Cell Res Ther 2009 Jan; 4 (1): 34-43
127. Gan Y, Dai K, Zhang P, et al. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008 Oct; 29 (29): 3973-3982
128. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002 Dec; (405): 14-23
129. Wakitani S, Nawata M, Tensho K, et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: Three case reports involving nine defects in five knees. J Tissue Eng Regen Med 2007 Feb; 1 (1): 74-9
130. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999 Mar; 5 (3): 309-313
131. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrowderived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002 Jun 25; 99 (13): 8932-7
132. Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy-A review ofUKdata for 2004. Haematologica 2006 Sep; 91 (9): 1293-4
133. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994 Oct 6; 331 (14): 889-895
134. Strauss EJ, Fonseca LE, Shah MR, et al. Management of focal cartilage defects in the knee: Is ACI the answer? Bull NYU Hosp Jt Dis 2011; 69 (1): 63-72
135. Bentley G, Biant LC, Carrington RWJ, et al. A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J Bone Joint Surg Br 2003 Mar; 85 (2): 223-230
136. Horas U, Pelinkovic D, Herr G, et al. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint: A prospective, comparative trial. J Bone Joint SurgAm2003 Feb; 85-A (2): 185-192
137. Basad E, Ishaque B, Bachmann G, et al. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: A 2-year randomised study. Knee Surg Sports Traumatol Arthrosc 2010 Apr; 18 (4): 519-527
138. Knutsen G, Drogset JO, Engebretsen L, et al. A randomized trial comparing autologous chondrocyte implantation with microfracture: Findings at five years. J Bone Joint Surg Am 2007 Oct; 89 (10): 2105-2112
139. Van Assche D, Staes F, Van Caspel D, et al. Autologous chondrocyte implantation versus microfracture for knee cartilage injury: A prospective randomized trial, with 2-year follow-up. Knee Surg Sports Traumatol Arthrosc 2010 Apr; 18 (4): 486-495
140. Gangji V, De Maertelaer V, Hauzeur J-P. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone 2011 Nov; 49 (5): 1005-9
141. Gangji V, Hauzeur J-P. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique. J Bone Joint Surg Am 2005 Mar; 87 Suppl. 1 (Pt 1): 106-112
142. Ochs BG, Schmid U, Rieth J, et al. Acetabular bone reconstruction in revision arthroplasty: A comparison of freeze-dried, irradiated and chemicallytreated allograft vitalised with autologous marrow versus frozen nonirradiated allograft. J Bone Joint Surg Br 2008 Sep; 90 (9): 1164-1171
143. Lee CH, Cook JL, Mendelson A, et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: A proof of concept study. Lancet 2010 Aug 7; 376 (9739): 440-8
144. Urist MR. Bone: Formation by autoinduction. Science 1965 Nov; 150 (698): 893-9
145. Urist MR, Dowell TA. Inductive substratum for osteogenesis in pellets of particulate bone matrix. Clin Orthop Relat Res 1968 Dec; 61: 61-78
146. Urist MR, Silverman BF, Büring K, et al. The bone induction principle. Clin Orthop Relat Res 1967 Aug; 53: 243-283
147. Pacaccio DJ, Stern SF. Demineralized bone matrix: Basic science and clinical applications. Clin Podiatr Med Surg 2005 Oct; 22 (4): 599-606
148. Han B, Tang B, Nimni ME. Quantitative and sensitive in vitro assay for osteoinductive activity of demineralized bone matrix. J Orthop Res 2003 Jul; 21 (4): 648-654
149. Ragni P, Lindholm TS. Interaction of allogeneic demineralized bone matrix and porous hydroxyapatite bioceramics in lumbar interbody fusion in rabbits. Clin Orthop Relat Res 1991 Nov; (272): 292-9
150. Drosos GI, Kazakos KI, Kouzoumpasis P, et al. Safety and efficacy of commercially available demineralised bone matrix preparations: A critical review of clinical studies. Injury 2007 Sep; 38 Suppl. 4: 13-21
151. Cammisa Jr FP, Lowery G, Garfin SR, et al. Two-year fusion rate equivalency between Grafton DBM gel and autograft in posterolateral spine fusion: A prospective controlled trial employing a side-by-side comparison in the same patient. Spine 2004 Mar; 29 (6): 660-6
152. Sassard WR, Eidman DK, Gray PM, et al. Augmenting local bone with Grafton demineralized bone matrix for posterolateral lumbar spine fusion: Avoiding second site autologous bone harvest. Orthopedics 2000 Oct; 23 (10): 1059-1065
153. Kang J, An H, Hilibrand A, et al. Grafton- & local bone has comparable outcomes to iliac crest bone in instrumented single level lumbar fusions. Spine. Epub 2011 Nov 8
154. Hierholzer C, Sama D, Toro JB, et al. Plate fixation of ununited humeral shaft fractures: Effect of type of bone graft on healing. J Bone Joint Surg Am 2006 Jul; 88 (7): 1442-7
155. Wang JC, Alanay A, Mark D, et al. A comparison of commercially available demineralized bone matrix for spinal fusion. Eur Spine J 2007 Aug; 16 (8): 1233-1240
156. Ferreira SD, Dernell WS, Powers BE, et al. Effect of gas-plasma sterilization on the osteoinductive capacity of demineralized bone matrix. Clin Orthop Relat Res 2001 Jul; (388): 233-9
157. Schwartz Z, Somers A, Mellonig JT, et al. Ability of commercial demineralized freeze-dried bone allograft to induce new bone formation is dependent on donor age but not gender. J Periodontol 1998 Apr; 69 (4): 470-8
158. Kinney RC, Ziran BH, Hirshorn K, et al. Demineralized bone matrix for fracture healing: Fact or fiction? JOrthop Trauma 2010Mar; 24 Suppl. 1: S52-5
159. Partridge KA, Oreffo ROC. Gene delivery in bone tissue engineering: Progress and prospects using viral and nonviral strategies. Tissue Eng 2004 Feb; 10 (1-2): 295-307
160. Caplan AI. Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res 2000 Oct; (379 Suppl.): 67-70
161. Pochampally RR, Horwitz EM, DiGirolamo CM, et al. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: A strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther 2005 Jul; 12 (14): 1119-1125
162. Evans C. Gene therapy for the regeneration of bone. Injury 2011 Jun; 42 (6): 599-604
163. Tran GT, Pagkalos J, Tsiridis E, et al. Growth hormone: Does it have a therapeutic role in fracture healing? Expert Opin Investig Drugs 2009 Jul; 18 (7): 887-911
164. Peichl P, Holzer LA, Maier R, et al. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011 Sep; 93 (17): 1583-7
165. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010 Feb; 25 (2): 404-414
166. Arrighi I, Mark S, Alvisi M, et al. Bone healing induced by local delivery of an engineered parathyroid hormone prodrug. Biomaterials 2009 Mar; 30 (9): 1763-1771
167. Yu X, Wei M. Preparation and evaluation of parathyroid hormone incorporated CaP coating via a biomimetic method. J Biomed Mater Res Part B Appl Biomater 2011 May; 97 (2): 345-354
168. Wroblewski BM. Professor Sir John Charnley (1911-1982). Rheumatology (Oxford) 2002 July; 41 (7): 824-5